Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00035024.xml
Download PDF
Thromb Haemost 2008; 99(06): 1119-1120
DOI: 10.1160/TH08-02-0081
DOI: 10.1160/TH08-02-0081
Letters to the Editor
The V617F JAK 2 mutation is not a frequent event in patients with cerebral venous thrombosis without overt chronic myeloproliferative disorder
Authors
Further Information
Publication History
Received
12 February 2008
Accepted after minor revision
20 April 2008
Publication Date:
28 November 2017 (online)
-
References
- 1 Campbell PJ, Green AR. The myeloproliferative disorders. N Engl J Med 2006; 355: 2452-2466.
- 2 Gruppo Italiano Studio Policitemia. Polycythemia Vera: the natural history of 1213 patients follow up for 20 years. Ann Int Med 1995; 123: 656-664
- 3 Bazzan M, Tamponi G, Schinco P. et al. Thrombosis-free survival and life expectancy in 187 consecutive patients with essential thrombocythemia. Ann Hematol 1999; 78: 539-543.
- 4 Bousser MG, Ferro JM. Cerebral venous thrombosis: an update. Lancet Neurol 2007; 6: 162-170.
- 5 Tefferi A, Elliott M. Thrombosis in myeloproliferative disorders : prevalence, prognostic factors and the role of leukocytes and JAK2V617F. Semin Thromb Hemost 2007; 33: 313-320
- 6 Campbell PJ, Scott LM, Buck G. et al. and the United Kingdom Myeloproliferative Disorders Study Group; Medical Research Council Adult Leukaemia Working Party; Australasian Leukaemia and Lymphoma Group. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 2005; 366: 1945-1953.
- 7 Randi ML, Lombardi AM, Scapin M. et al. Haemostatic proteins gene polymorphisms in patients with unusual vein thrombosis and Ph-myeloproliferative disorders. Thromb Haemost 2007; 98: 702-704.
- 8 Colaizzo D, Amitrano L, Tiscia GL. et al. The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis. J Thromb Haemost 2007; 5: 55-61.
- 9 De Stefano V, Fiorini A, Rossi E. et al. Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders. J Thromb Haemost 2007; 5: 708-714.
- 10 Tefferi A, Thiele J, Orazi A. et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 2007; 110: 1092-1097.
- 11 Kiladjian JJ, Cassinat B, Turlure P. et al. High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a. Blood 2006; 108: 2037-2040.
- 12 Ferro JM, Canhão P, Stam J. et al. and the ISCVT Investigators. Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT). Stroke 2004; 35: 664-670.